Patents by Inventor Michael Enrico Richett

Michael Enrico Richett has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • IL-17A INHIBITORS
    Publication number: 20220073526
    Abstract: The invention provides certain difluorocyclohexyl-imidazopyridazinyl-imidazolidinone compounds of formula II as IL-17A inhibitors, pharmaceutical compositions thereof, and methods of using a compound of formula II to treat certain symptoms of psoriasis, rheumatoid arthritis or multiple sclerosis.
    Type: Application
    Filed: January 3, 2020
    Publication date: March 10, 2022
    Inventors: David Andrew Coates, Kwame Frimpong, William Glen Holloway, Brian Spencer Jones, Adam Marc Levinson, Charles Willis Lugar, III, Michael Enrico Richett, Brian Morgan Watson, Michael Edward Woodman
  • Inhibitors of EZH2
    Patent number: 9718838
    Abstract: The present invention relates to compounds that inhibit activity of the histone lysine methyltransferase, Enhancer of Zeste Homolog 2 (EZH2), pharmaceutical compositions comprising the compounds, and methods of using the compounds to treat cancer, such as hematologic and solid tumors.
    Type: Grant
    Filed: August 22, 2016
    Date of Patent: August 1, 2017
    Assignee: Eli Lilly and Company
    Inventors: Deqi Guo, Anh-Quan Hannah Nguyen, Michael Enrico Richett
  • INHIBITORS OF EZH2
    Publication number: 20170066780
    Abstract: The present invention relates to compounds that inhibit activity of the histone lysine methyltransferase, Enhancer of Zeste Homolog 2 (EZH2), pharmaceutical compositions comprising the compounds, and methods of using the compounds to treat cancer, such as hematologic and solid tumors.
    Type: Application
    Filed: August 22, 2016
    Publication date: March 9, 2017
    Inventors: Esteban DOMINGUEZ, Deqi GUO, Mary Margaret MADER, Anh-Quan Hannah NGUYEN, Miriam DEL PRADO, Michael Enrico RICHETT, Michael John RODRIGUEZ, Yvonne Yee Mai YIP, Kuo-Long YU
  • Benzisothiazol-3-one-carboxylic acid amides as phospholipase inhibitors
    Patent number: 7595403
    Abstract: A novel class of benzisothiazole-3(2H)-one compounds is disclosed together with the use of such compounds for inhibiting hepatic lipase and/or endothelial lipase activity for treatment, amelioration or prevention of hepatic lipase and/or endothelial lipase mediated diseases.
    Type: Grant
    Filed: March 25, 2004
    Date of Patent: September 29, 2009
    Assignee: Eli Lilly and Company
    Inventors: Patrick Irving Eacho, Patricia Sue Foxworthy-Mason, Ho-Shen Lin, Jose Eduardo Lopez, Marian Kazimierz Mosior, Michael Enrico Richett
  • [4-(Benzo[B]thiophen-2-yl) Pyrimidin-2-yl]-amine derivatives as IKK-beta inhibitors for the treatment of cancer and inflammatory diseases
    Patent number: 7547691
    Abstract: The present invention provides compounds of Formula I: useful in the treatment of cancer and inflammatory diseases.
    Type: Grant
    Filed: November 15, 2006
    Date of Patent: June 16, 2009
    Assignee: Eli Lilly and Company
    Inventors: Karl Robert Dahnke, Ho-Shen Lin, Michael Enrico Richett, Chuan Shih, Q May Wang, Bo Zhang
  • ANTITUMOR BENZOYLSULFONAMIDES
    Publication number: 20090118323
    Abstract: The present invention provides antitumor compounds of the formula (I); and antitumor methods.
    Type: Application
    Filed: September 11, 2007
    Publication date: May 7, 2009
    Inventors: Mary Margaret Mader, Luisa Maria Martin-Cabrejas, Michael Enrico Richett
  • [4-(Benzo[B]Thiophen-2-Yl) Pyrimidin-2-Yl]-Amine Derivatives As Ikk-Beta Inhibitors For The Treatment Of Cancer And Inflammatory Diseases
    Publication number: 20080306082
    Abstract: The present invention provides compounds of Formula I: useful in the treatment of cancer and inflammatory diseases.
    Type: Application
    Filed: November 15, 2006
    Publication date: December 11, 2008
    Inventors: Karl Robert Dahnke, Ho-Shen Lin, Michael Enrico Richett, Chuan Shih, Q May Wang, Bo Zhang
  • 7-phenyl-isoquinoline-5-sulfonylamino derivatives as inhibitors of akt (protein kinase B)
    Patent number: 7449477
    Abstract: The present invention relates to compounds Formula (I) as inhibitors of AKT activity, which are useful for the treatment of susceptible neoplasms and viral infections.
    Type: Grant
    Filed: November 22, 2004
    Date of Patent: November 11, 2008
    Assignee: Eli Lilly and Company
    Inventors: David Anthony Barda, Kenneth James Henry, Jr., Jianping Huang, Sajan Joseph, Ho-Shen Lin, Michael Enrico Richett
  • Inhibitors of Akt (protein kinase B)
    Patent number: 7414063
    Abstract: The present invention relates to compounds Formula (I): as inhibitors of AKT activity, which are useful for the treatment of susceptible neoplasms and viral infections.
    Type: Grant
    Filed: March 25, 2004
    Date of Patent: August 19, 2008
    Assignee: Eli Lilly and Company
    Inventors: Rima Salim Al-Awar, David Anthony Barda, Albert Gerard Dee, Kenneth James Henry, Jr., Sajan Joseph, Ho-Shen Lin, Jose Eduardo Lopez, Michael Enrico Richett, Carmen Somoza
  • Antitumor benzoylsulfonamides
    Patent number: 7282595
    Abstract: The present invention provides antitumor compounds of the formula (I); and antitumor methods.
    Type: Grant
    Filed: November 13, 2003
    Date of Patent: October 16, 2007
    Assignee: Eli Lilly and Company
    Inventors: Mary Margaret Mader, Luisa Maria Martin-Cabrejas, Michael Enrico Richett
  • Thiophene-and thiazolesulfonamides as antineoplastic agents
    Patent number: 7250430
    Abstract: The present invention provides antineoplastic compounds of the formula: and antineoplastic methods.
    Type: Grant
    Filed: June 6, 2006
    Date of Patent: July 31, 2007
    Assignee: Eli Lilly and Company
    Inventors: Cora Sue Grossman, Philip Arthur Hipskind, Ho-Shen Lin, Karen Lynn Lobb, Beatriz Lopez de Uralde Garmendia, Jose Eduardo Lopez, Mary Margaret Mader, Michael Enrico Richett, Chuan Shih, Alfonso De Dios
  • Phospholipase inhibitors
    Patent number: 7217727
    Abstract: A novel class of 3-oxo-3H-benzo[d]isoxazole carboxamide compounds is disclosed together with the use of such compounds for inhibiting hepatic lipase and/or endothelial lipase activity for treatment, amelioration or prevention of hepatic lipase and/or endothelial lipase mediated diseases.
    Type: Grant
    Filed: March 25, 2004
    Date of Patent: May 15, 2007
    Assignee: Eli Lilly and Company
    Inventors: Patrick Irving Eacho, Patricia Sue Foxworthy-Mason, Ho-Shen Lin, Jose Eduardo Lopez, Marian Kazimierz Mosior, Michael Enrico Richett
  • Thiophene-amd thiazolesulfonamides as antineoplastic agents
    Patent number: 7084170
    Abstract: The present invention provides antineoplastic compounds of the formula: and antineoplastic methods.
    Type: Grant
    Filed: October 15, 2002
    Date of Patent: August 1, 2006
    Assignee: Eli Lilly and Company
    Inventors: Cora Sue Grossman, Philip Arthur Hipskind, Ho-Shen Lin, Karen Lynn Lobb, Beatriz Lopez de Uralde Garmendia, Jose Eduardo Lopez, Mary Margaret Mader, Michael Enrico Richett, Chuan Shih, Alfonso De Dios
  • sPLAinhibitors
    Patent number: 6992100
    Abstract: A novel class of tetracyclic compounds is disclosed together with the use of such compounds for inhibiting sPLA2 mediated release of fatty acids for treatment of Inflammatory Diseases such as septic shock.
    Type: Grant
    Filed: December 6, 2001
    Date of Patent: January 31, 2006
    Assignee: Eli Lilly and Company
    Inventors: Douglas Wade Beight, Michael Dean Kinnick, Ho-Shen Lin, John Michael Morin, Jr., Michael Enrico Richett, Daniel Jon Sall, Jason Scott Sawyer, John David Jandzinski
  • sPLA2 inhibitors
    Patent number: 6974831
    Abstract: A novel class of cycloalkyl fused indole compounds is disclosed together with the use of such compounds for inhibiting sPLA2 mediated release of fatty acids for treatment of Inflammatory Diseases such as septic shock.
    Type: Grant
    Filed: December 6, 2001
    Date of Patent: December 13, 2005
    Assignee: Eli Lilly and Company
    Inventors: Douglas Wade Beight, Michael Dean Kinnick, Ho-Shen Lin, John Michael Morin, Michael Enrico Richett, Daniel Jon Sall, Jason Scott Sawyer, Edward C R Smith
  • sPLA2 inhibitors
    Patent number: 6939890
    Abstract: A class of novel indole is disclosed together with the use of such compounds for inhibiting sPLA2 mediated release of fatty acids for treatment of Inflammatory Diseases such as septic shock.
    Type: Grant
    Filed: July 30, 2003
    Date of Patent: September 6, 2005
    Assignee: Eli Lilly and Company
    Inventors: Richard Waltz Harper, Ho-Shen Lin, Michael Enrico Richett
  • Substituted carbazoles as inhibitors of sPLA2
    Patent number: 6933313
    Abstract: Carbazoles of formula (I) with R2=hydroxyfunctional amide (hydroxamic or esters) are disclosed together with the use of such compounds for inhibiting sPLA2 mediated release of fatty acids for treatment of conditions such as septic shock.
    Type: Grant
    Filed: March 15, 2002
    Date of Patent: August 23, 2005
    Assignee: Eli Lilly and Company
    Inventors: Richard Waltz Harper, Ho-Shen Lin, Michael Enrico Richett
  • sPLA2 inhibitors
    Patent number: 6930123
    Abstract: A novel class of benz[f]indole compounds is disclosed together with the use of such compounds for inhibiting sPLA2 mediated release of fatty acids for treatment of Inflammatory Diseases such as septic shock.
    Type: Grant
    Filed: December 6, 2001
    Date of Patent: August 16, 2005
    Assignee: Eli Lilly and Company
    Inventors: Douglas Wade Beight, Michael Dean Kinnick, Ho-Shen Lin, John Michael Morin, Michael Enrico Richett, Daniel Jon Sall, Jason Scott Sawyer, Edward C R Smith
  • Spla2 inhibitors
    Patent number: 6916840
    Abstract: A novel class of benz[g]indole compounds is disclosed together with the use of such compounds for inhibiting sPLA2 mediated release of fatty acids for treatment of Inflammatory Diseases such as septic shock.
    Type: Grant
    Filed: December 6, 2001
    Date of Patent: July 12, 2005
    Assignee: Eli Lilly and Company
    Inventors: Douglas Wade Beight, Michael Dean Kinnick, Ho-Shen Lin, John Michael Morin, Jr., Michael Enrico Richett, Daniel Jon Sall, Jason Scott Sawyer, Edward C R Smith
  • sPLA2 inhibitors
    Patent number: 6872743
    Abstract: A novel class of tetracyclic compounds represented by the formula I wherein R1, R2, R3, R4, R5, R6, R7, A, B, C, D, E, and n are as defined is disclosed together with the use of such compounds for inhibiting sPLA2 mediated release of fatty acids for treatment of Inflammatory Diseases such as septic shock.
    Type: Grant
    Filed: December 6, 2001
    Date of Patent: March 29, 2005
    Assignee: Eli Lilly and Company
    Inventors: Douglas Wade Beight, Michael Dean Kinnick, Ho-Shen Lin, John Michael Morin, Jr., Michael Enrico Richett, Daniel Jon Sall, Jason Scott Sawyer